arGEN-X BV (ARGX) Expected to Post Quarterly Sales of $8.56 Million

Brokerages forecast that arGEN-X BV (NASDAQ:ARGX) will report $8.56 million in sales for the current fiscal quarter, according to Zacks. Three analysts have made estimates for arGEN-X BV’s earnings, with the highest sales estimate coming in at $9.35 million and the lowest estimate coming in at $7.35 million. The business is expected to issue its next earnings results on Monday, January 1st.

On average, analysts expect that arGEN-X BV will report full year sales of $29.88 million for the current fiscal year, with estimates ranging from $19.66 million to $39.36 million. For the next year, analysts forecast that the business will report sales of $27.24 million per share, with estimates ranging from $15.27 million to $39.20 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that cover arGEN-X BV.

ARGX has been the subject of several research reports. Zacks Investment Research cut shares of arGEN-X BV from a “buy” rating to a “hold” rating in a research note on Tuesday, January 2nd. JMP Securities increased their target price on shares of arGEN-X BV from $74.00 to $87.00 and gave the company an “outperform” rating in a research note on Monday, January 29th. Finally, SunTrust Banks initiated coverage on shares of arGEN-X BV in a research note on Sunday, April 8th. They issued a “buy” rating and a $125.00 target price for the company. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company. arGEN-X BV presently has an average rating of “Buy” and a consensus target price of $86.00.

Shares of NASDAQ ARGX traded down $0.26 during mid-day trading on Friday, hitting $88.90. The company had a trading volume of 172,998 shares, compared to its average volume of 108,730. arGEN-X BV has a 12 month low of $17.33 and a 12 month high of $90.20.

ILLEGAL ACTIVITY NOTICE: “arGEN-X BV (ARGX) Expected to Post Quarterly Sales of $8.56 Million” was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://www.chaffeybreeze.com/2018/04/22/argen-x-bv-argx-expected-to-post-quarterly-sales-of-8-56-million.html.

About arGEN-X BV

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

Get a free copy of the Zacks research report on arGEN-X BV (ARGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for arGEN-X BV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for arGEN-X BV and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply